On June 5, 2014, Nina Bhardwaj, M.D., Ph.D., the Director of Immunotherapy and the Medical Director of the Vaccine and Cell Therapy Core facility at Icahn School of Medicine at Mount Sinai, discussed current immunotherapy treatment options for patients with melanoma, and how close we are to making these treatments available to more patients.
Nina Bhardwaj, M.D., Ph.D., is the Director of Immunotherapy and the Medical Director of the Vaccine and Cell Therapy Core facility at Icahn School of Medicine at Mount Sinai. She is an expert on human dendritic cell (DC) subsets, specifically with respect to their isolation, biology, function, and use as vaccine adjuvants in humans. She has been principal investigator for the design and implementation of several clinical trials studying novel experimental immunotherapies for melanoma and other cancers using Toll-like receptor (TLR) agonists or dendritic cells as adjuvants. Her lab also investigates DC biology in the tumor micro-environment as it relates to anti-melanoma immunity. Dr. Bhardwaj earned her M.D. and Ph.D. degrees from New York University School of Medicine and completed her postdoctoral training at The Rockefeller University.
This webinar is part of the Cancer Research Institute's webinar series, "Cancer Immunotherapy and You," which are offered free to the public and feature informative updates for patients and caregivers from leaders in cancer immunotherapy, followed by a Q&A. This webinar was generously supported by Bristol-Myers Squibb. For more information on this webinar, or to register for upcoming webinars, please visit www.cancerresearch.org/webinars.